April 15, 2021
Article
A phase 3 trial has already been launched to build on these early results with the combination of the PARP inhibitor and androgen receptor inhibitor.
April 13, 2021
Tumors exhibiting homozygous DNA damage response (DDR) alterations were more likely to respond to talazoparib than those with heterozygous DDR alterations.
April 12, 2021
Maintaining a healthy lifestyle lowered the likelihood of developing aggressive prostate cancer among men with high genetic risk.
April 09, 2021
Video
Jason Zhu, MD, discusses factors he considers when choosing treatment for patients with lymph node–positive prostate cancer after prostatectomy.
April 07, 2021
Ward's analysis includes a discussion of adjuvant radiotherapy versus early salvage radiotherapy.
April 06, 2021
Using a blood or saliva sample, ProstateNow employs a 3-pronged approach for assessing risk.
“This test requires just one millimeter of cancer on a biopsy on five consecutive slides,” says Eric A. Klein, MD.
April 02, 2021
The PARP inhibitors olaparib and rucaparib are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer.
April 01, 2021
Robert Dreicer, MD, discusses emerging strategies for overcoming resistance to second-generation antiandrogens in prostate cancer.
March 31, 2021
Leonard G. Gomella, MD, discusses questions that still need to be resolved with biomarkers for the diagnosis and management of patients with prostate cancer.
March 30, 2021
The trend persists even after adjusting for surgical volume and experience.
March 29, 2021
Scott T. Tagawa, MD, highlights pivotal research and next steps with the alpha particle–emitting radioactive therapeutic agent radium-223 in prostate cancer.
March 26, 2021
The European Commission is reviewing supporting data from the phase 3 ARCHES trial.
March 25, 2021
Dr. Leonard G. Gomella discusses emerging biomarkers and the use of MRI for the early detection of prostate cancer.
March 24, 2021
“This study represents the most comprehensive analysis to date of tumor mutation burden as a biomarker for response to immune checkpoint blockade,” according to lead study author Daniel J. McGrail, PhD.
Transperineal prostate biopsy was associated with a higher likelihood of upgrading to clinically significant prostate cancer versus transrectal prostate biopsy among men on active surveillance.
“The way I think about this test now is… more as a dichotomous score,” says Eric A. Klein, MD.
March 23, 2021
The targeted radioligand therapy 177Lu-PSMA-617 also improved progression-free survival when added to best standard of care (BSC) compared with BSC alone.
March 22, 2021
Scott T. Tagawa, MD, explained the latest developments with the radiopharmaceutical radium-223 at the 2021 New York GU 14th Annual Interdisciplinary Prostate Cancer Congress®.
“It’s really fascinating how the field is expanding,” Klein says.
